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Accepted 8 May 2013With increasing numbers of hematopoietic stem cell
transplantations (HSCT) performed yearly worldwide and
the improvement of the outcomes after transplantation, the
number of long-term survivors is continually increasing.
Recipients of HSCT surviving more than10 years may have
reached their aimdcure of their primary diseasedfor which
they underwent transplantation. Therefore, they turn their
attention to normal health and well-being. After the long
road of transplantation, patients wish to return to normal
life.
How realistic are these expectations of the long-term
survivors and their family? For more than 30 years now,
late complications and quality of life after HSCT have been
a major issue. HSCT remains associated with considerable
late morbidity and mortality. Many late complications, such
as secondary cancer, cataract development, endocrine
dysfunction, infertility, bone and joint degeneration, and
cardiovascular and cardiac complications have been well
described [1]. Moreover, within 10 to 30 years after trans-
plantation, mortality rates are still increased, being 4-fold to
9-fold higher than observed in an age-adjusted general
population. This excess of deaths emerges as the expression
of the underlying morbidity affecting this population. A
previous study has shown that the burden of morbidity at 10
years after HSCT was high and that two-thirds of the patients
had a least 1 chronic health condition. Among severe health
conditions, gastrointestinal complications, musculoskeletal
problems, and cardiovascular events were the most common
ﬁndings [2]. However, with longer follow-up, the list of
possible complications may continue to increase.
In this issue of Biology of Blood and Marrow Trans-
plantation, Sun et al. extend their analysis to chronic health
conditions in patients who survived HSCT 10 years or longer
[3]. The authors demonstrate that the burden of physical and
emotional morbidity in long-term survivors is still substan-
tial. The cumulative incidence of developing any chronic
health condition increases up to 71% and, for severe or life-
threatening conditions, up to 41%. Furthermore, compared
to siblings, survivors were 2.7 times more likely to report
somatic distress. This high burden of morbidity in long-term
survivors seems somehow in contradiction with the survi-
vors’ health perception. Indeed, despite survivors reporting
less good health status than siblings, nearly 9 of 10 survivors
perceived their health status as “good” or even “excellent.”Financial disclosure: See Acknowledgments on page 1005.
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threatening morbidity, most of the long-term survivors
seem satisﬁed with their health and well-being. Among
others, 3 issues are of particular interest in this important
study: ﬁrst, both types of treatment, autologous and alloge-
neic HSCT, are associated with risk of chronic health condi-
tions in patients surviving 10 years or longer; second, despite
the high burden of chronic health condition and physical
distress, most of the long-term survivors had a positive
perception of their health status; and third, less than one
third of the long-term survivors reported that their cancer/
transplantation visits were performed at the transplantation
center independently of the severity of health condition.
We have now a good knowledge of the type of late effects
that may occur and the risk factors involved. Despite most of
the late effects described pertaining to allogeneic HSCT,
a burden of late complications and increased mortality has
also been demonstrated in patients who survived at least
5 years after autologous HSCT. However, among patients
with standard risk for relapse surviving 10 years after HSCT,
mortality rates approach those of the general population [4].
For many transplantation clinicians, the opinion prevails that
relapse is the major risk for patients treated with autologous
HSCT, and that after these patients have survived 10 years
without relapse, the risk of morbidity and mortality is no
longer increased, and therefore the patients do no longer
need special posttransplantation controls.
Sun et al. brought some light on this matter. They showed
clearly that there is no difference in the cumulative incidence
of chronic health conditions after 10 years. Autologous
transplantation recipients do not have less long-term
morbidity than allogeneic HSCT recipients, but they have
different types of late effects. Allogeneic HSCT recipients
were more likely to be at risk for chronic graft-versus-host
disease and immunosuppressive treatment-related compli-
cations, and autologous HSCT recipients developed late
effects more in relation with the treatment received before
transplantation. Today, we have a fairly good map for the
distribution of complications that may occur in a patient
surviving 10 years or longer. Depending on the type of HSCT
(autologous or allogeneic), the conditioning regimen used
(total body irradiation or not) and the presence of chronic
graft-versus-host disease, patient-speciﬁc long-term follow-
up can be individualized. The increasing awareness of late
complications has already led to modiﬁcations of trans-
plantation strategies aiming at a better response with less
toxicity.
Some long-term survivors after HSCT affected by
a number of late complications may consider themselves
satisﬁed with their physical andmental condition. Subjective
feeling of well-being is strongly related to the individual’s
expectations of health. Although the positive perception of
health condition appears paradoxical with the physical
impairment, these ﬁndings may reﬂect the ability of the
transplantation recipient to adapt to more realistic expec-
tations in accepting his limitations. Furthermore, over-
coming traumatic experiences caused by a life-threatening
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greater appreciation of life and, therefore, to a better quality
of life [5]. Another explanation for these apparently para-
doxical ﬁndings could be that some of the chronic health
conditions may not, or not yet, affect the well-being of the
long-term recipients either because the condition has been
treated (ie, cataract, endocrine dysfunction) or because the
chronic health condition is still asymptomatic (ie, arterial
hypertension, dyslipidemia). Nevertheless, a positive
perception of health should not contribute to ignoring the
necessity of regular posttransplantation surveillance.
The need for long-term surveillance, preventive practices,
and early treatment after HSCT has been recognized and is
now universally well accepted [6]. However, according to the
study by Sun et al., less than one third of the recipients
surviving 10 years and longer regularly visit a specialist for
long-term complications. Several reasons may explain these
ﬁgures: long distance between the transplantation center
and the patient’s home; lack of insurance covering the
follow-up at the HSCT center; and some long-term survivors
may prefer to create a distance from their painful experience
and avoid contact with the transplantation center, whereas
others may consider, having been cured from their primary
disease, there is no longer the need for the controls of
a specialized center. Long-term survivors need to be advised
and convinced that specialized long-term follow-up will be
crucial for their long-term well-being.
Sun et al. addressed, in the present study, a major issue in
the ﬁeld of long-term survivorship. This quote, supposedly
from Albert Einstein, ﬁts the present matter well: “A clever
person solves a problem; a wise person avoids it.” Indeed,
targeted screening and preventive measures are the basis of
the long-term survivorship care in transplantation recipi-
ents. As a simple example, it makes much more sense to
prevent or correct cardiovascular risk factors than to treat
cardiovascular complications occurring after HSCT.
Long-term follow-up after HSCT has taught us that
long-term survivors, provided their primary disease waseradicated, may return somehow to normal life; still, they
will need close and specialized surveillance. However, being
aware that life-long controls after HSCT are mandatory is not
sufﬁcient. Convincing long-term survivors, their families,
general health care providers, as well as the health authori-
ties of the need for persuasive counseling and education on
late effects surveillance is one of the challenges to face in the
forthcoming years.
As preventive medicine is the foundation for a good
health care system, prevention in specialized hands is the
clue to guarantee good health conditions in long-term
survivorship. Specialized preventive medicine for cancer
and transplantation survivors arise indeed as a necessity in
today’s world where all parties involved should contribute to
achieving all unmet needs.ACKNOWLEDGMENTS
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